Back to Search
Start Over
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.
- Source :
- Medicina (1010660X); Nov2022, Vol. 58 Issue 11, p1543, 9p
- Publication Year :
- 2022
-
Abstract
- Objectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to compare their outcomes with younger subjects. Methods: Institutional registries across three academic medical centers were retrospectively reviewed. The Kaplan–Meier methods were used to estimate survival, and the log-rank test was used to make comparisons. Results: A total of 190 BTC patients treated with 2L were identified and included in the analysis. Among them, 52 (27.3%) were aged ≥ 70 years (range 70–87 years). No statistically significant differences in both median overall survival (mOS) and median progression-free survival (mPFS) were recorded between the elderly and younger patients. Absolute lymphocyte count < 1000/mmc (p < 0.001) and albumin level < 3 g/dL (p < 0.001) were independently associated with worse prognoses. Conclusions: The results of this real-world study suggest that for patients aged ≥ 70 years, 2L could be equally effective for younger patients with survival outcomes aligned to those from the ABC-06 and NIFTY trials. The delivery of 2L should be carefully evaluated and monitored in this patient subset. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1010660X
- Volume :
- 58
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Medicina (1010660X)
- Publication Type :
- Academic Journal
- Accession number :
- 160205489
- Full Text :
- https://doi.org/10.3390/medicina58111543